

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRINCIPAL FINANCIAL INFORMATION OF CR JIANGZHONG FOR THE YEAR ENDED 31 DECEMBER 2025

On 19 March 2026, CR Jiangzhong released its annual report for the year ended 31 December 2025.

China Resources Jiangzhong Pharmaceutical Co., Ltd. (華潤江中藥業股份有限公司) (“**CR Jiangzhong**”) is a company incorporated in the People’s Republic of China. The shares of CR Jiangzhong are listed on the Shanghai Stock Exchange. As of the date of this announcement, CR Jiangzhong is owned as to approximately 43.14% equity interest by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) through its non-wholly owned subsidiary, China Resources Jiangzhong Pharmaceutical Group Co., Ltd. (華潤江中製藥集團有限責任公司). The Group controls an effective interest of approximately 26.12% of CR Jiangzhong, which is accounted for as a subsidiary of the Company.

On 19 March 2026, CR Jiangzhong released its annual report for the year ended 31 December 2025 (the “**CR Jiangzhong Audited Annual Financials**”). Set out below are the key financial information of the CR Jiangzhong Audited Annual Financials:

	As of 31 December 2025 (RMB) (Audited)	As of 31 December 2024 (RMB) (Audited)	Increase (%)
Total assets	6,880,863,149.41	6,507,939,655.60	5.73%
Net assets attributable to shareholders of the listed company	4,022,814,419.53	3,862,808,649.61	4.14%

	For the year ended 31 December		Increase/ decrease
	2025	2024	
	(RMB)	(RMB)	(%)
	(Audited)	(Audited)	
Revenue	4,219,503,334.92	4,435,450,590.73	-4.87%
Net profit attributable to the shareholders of the listed company	906,685,963.56	788,192,557.44	15.03%
Net profit attributable to the shareholders of the listed company (excluding extraordinary gains or losses)	833,261,416.65	749,175,142.75	11.22%
Net cash flow from operating activities	970,867,419.63	786,252,548.91	23.48%
Basic earnings per share (RMB/share)	1.43	1.25	14.40%
Diluted earnings per share (RMB/share)	1.43	1.25	14.40%
Weighted average return on net asset (%)	22.75%	19.58%	3.17 percentage points

As determined by the board of directors of CR Jiangzhong, CR Jiangzhong proposed to distribute a cash dividend of RMB8.80 (inclusive of tax) for every 10 shares to all CR Jiangzhong's shareholders based on the total share capital of CR Jiangzhong on the date of equity distribution registration. Such proposal shall be submitted for shareholders' approval at CR Jiangzhong's 2025 annual general meeting.

The CR Jiangzhong Audited Annual Financials have been prepared and audited in accordance with the PRC Generally Accepted Accounting Principles. The financial information is limited to CR Jiangzhong only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Jiangzhong Audited Annual Financials, please refer to the annual report for the year ended 31 December 2025 published by CR Jiangzhong on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 19 March 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.